Neoplasm, Residual
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Our method could be applied to 97% of FLT3-ITD-positive patients and was as sensitive as other MRD parameters such as PML-RARA , NPM1 mutations, or MLL -PTD (correlation: r = 0.63; 0.99, and 0.99, respectively).
|
22458420 |
2012 |
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
PML/RARa-based MRD monitoring by RQ-PCR may allow us to identify subgroups of patients at low risk of relapse after induction.
|
22407853 |
2012 |
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Longitudinal RT-PCR of PML/RARalpha allows sensitive assessment of response to treatment and minimal residual disease (MRD) monitoring in APL.
|
17217043 |
2007 |
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The detection of PML-RARalpha by real-time polymerase chain reaction (RQ-PCR) is becoming an important tool for monitoring minimal residual disease (MRD) in patients with acute promyelocytic leukemia (APL).
|
17339180 |
2007 |
Neoplasm, Residual
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
The detection of the PML-RARA fusion gene by reverse-transcription polymerase chain reaction (RT-PCR) is routinely used for diagnosis and monitoring of minimal residual disease (MRD).
|
15179005 |
2004 |
Neoplasm, Residual
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
A total of 98 samples, comprising four groups, were evaluated: Group 1, 16 diagnostic samples molecularly positive by our existing laboratory-developed assays for PML-RARalpha/t (15;17) or BCR-ABL/t (9;22); Group 2, 51 diagnostic samples negative by our laboratory-developed assays for PML-RARalpha/t (15;17) or BCR-ABL/t (9;22); Group 3, 21 prospectively analyzed diagnostic cases, without prior molecular studies; and Group 4, 10 minimal residual disease (MRD) samples.
|
14573782 |
2003 |
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Recent studies suggest that rigorous MRD monitoring, coupled with pre-emptive therapy at the point of molecular relapse improves survival in the relatively small subgroup of PML-RARalpha positive patients with 'poor risk' disease.
|
12357347 |
2002 |
Neoplasm, Residual
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Acute promyelocytic leukaemia (APL) is characterized by the t(15;17)(q22;q21) leading to the formation of PML-RARalpha and RARalpha-PML fusion genes which provide suitable targets for the assessment of minimal residual disease (MRD).
|
11987921 |
2002 |
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Pulsed ATRA as single therapy restores long-term remission in PML-RARalpha-positive acute promyelocytic leukemia patients: real time quantification of minimal residual disease. A pilot study.
|
11681409 |
2001 |
Neoplasm, Residual
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Serial quantitation of MRD in both BM and PB samples showed significantly lower levels of PML-RARalpha transcripts in remission, although the majority of samples remain positive for the PML-RARalpha transcripts even those in long-term remission (up to 94 months).
|
11455974 |
2001 |
Neoplasm, Residual
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
We studied retrospectively the clinical feasibility of minimal residual disease (MRD) monitoring by reverse transcription-polymerase chain reaction (RT-PCR) detecting the PML/retinoic acid receptor alpha (RARalpha) chimeric gene in children with acute promyelocytic leukemia (APL).
|
11318028 |
2001 |
Neoplasm, Residual
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Minimal residual disease (MRD) was prospectively monitored at the 10(-5) level by the reverse transcriptase-polymerase chain reaction (RT-PCR) of PML-retinoic acid receptor alpha (RARA) transcripts from 27 acute promyelocytic leukemia (APL) patients who achieved complete remission (CR) with all-trans retinoic acid and chemotherapy (previously untreated patients, 15; refractory to chemotherapy or relapsed, 12).
|
7723389 |
1995 |
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Appropriate oligoprimers complementary to PML and RAR-a sequences nearby the DNA breakpoints may be successfully used in PCR experiments to amplify the PML/RAR-a hybrid gene and sensitively detect minimal residual disease.
|
8180596 |
1994 |
Neoplasm, Residual
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
The RT/PCR procedure has been established to characterize the expression patterns of the PML-RARA fusion gene and to detect minimal residual disease (MRD).
|
1337847 |
1992 |
Neoplasm, Residual
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
The t(15;17) breakpoint in acute promyelocytic leukemia cluster within two different sites of the myl gene: targets for the detection of minimal residual disease by the polymerase chain reaction.
|
1310060 |
1992 |
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The consistent identification by RT-PCR of the fusion of the PML and RAR alpha genes in AML3 patients suggest that this method will provide a useful tool for the diagnosis and detection of minimal residual disease in these patients.
|
1375840 |
1992 |